Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Arm Open-Label Study to Evaluate the Therapeutic Effects and Safety of a 6-Week Treatment Regimen of ALK4290 in Patients with Refractory Wet Age-Related Macular Degeneration (wAMD).

Trial Profile

A Single Arm Open-Label Study to Evaluate the Therapeutic Effects and Safety of a 6-Week Treatment Regimen of ALK4290 in Patients with Refractory Wet Age-Related Macular Degeneration (wAMD).

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Dec 2018

At a glance

  • Drugs AKST 4290 (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Sponsors Alkahest
  • Most Recent Events

    • 17 Dec 2018 Results presented in an Alkahest Media Release.
    • 04 Dec 2018 Status changed from recruiting to completed.
    • 14 May 2018 According to a media release, this study will be conducted in Hungary and Poland.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top